Apimeds Pharmaceuticals US, Inc. is a clinical stage biopharmaceutical company that engages in the development of Apitox, an intradermally administered bee venom-based toxin. The company is headquartered in Matawan, New Jersey and currently employs 2 full-time employees. The company went IPO on 2025-05-09. The firm is engaged in developing Apitox, an intradermally administered bee venom-based toxin. The company is focused on developing Apitox in the treatment of inflammatory conditions in the United States, specifically osteoarthritis and multiple sclerosis. Its subsidiary, MindWave Innovations Inc, is a provider of institutional digital asset treasury (DAT) solutions.
APUS stock price ended at $1.88 on 木曜日, after rising 7.43%
On the latest trading day Apr 02, 2026, the stock price of APUS rose by 7.43%, climbing from $1.69 to $1.88. During the session, the stock saw a volatility of 11.83%, with prices oscillating between a daily low of $1.69 and a high of $1.89. Notably, trading volume dropped by 6.4K shares on the last day despite the price increase, which may signal a potential uptick in risk in the near term. A total of 31.5K shares were traded, equating to a market value of approximately $23.6M.